News for Inovio Pharmaceuticals, Inc. (0A43.L)

California-based Bolt Projects Holdings, Inc. (BSLK) is up over 114 percent in Friday's pre-market trading. The following are some of the other stocks making big moves in Friday's pre-market trading.

In recent analyst activity, RBC Capital has reiterated its "Sector Perform" rating for Inovio Pharmaceuticals (INO). The rating remains unchanged, emphasizing t

Inovio Pharmaceuticals (INO) recently experienced a revision in its price target from Oppenheimer. Analyst Jay Olson has adjusted the price target from a previo

Operating Expenses: Decreased from $31.5 million in Q1 2024 to $25.1 million in Q1 2025, a 20% reduction.Net Loss: $19.7 million or $0.51 per share in Q1 2025,

May 13, 2025 / 08:30PM GMTOperator Good afternoon, ladies and gentlemen, and welcome to the Inovio First Quarter 2025 Financial Results Conference Call. [Operat

Inovio Pharmaceuticals is set to begin its BLA submission for INO-3107 by mid-2025. Operating expenses dropped by 20% in Q1 2025, with a significant dec

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Q1 2025 Earnings Conference Call May 13, 2025 4:30 PM ETCompany ParticipantsJennie Willson - IRJacqui Shea -...

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Citizens JMP Life Sciences Conference May 8, 2025 11:30 AM ETCompany ParticipantsJacqui Shea - President and...

PR NewswirePLYMOUTH MEETING, Pa., April 30, 2025 PLYMOUTH MEETING, Pa., April 30, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused

INOVIO (INO) to showcase INO-3107 in May 2025 at several major scientific conferences. INO-3107 demonstrates 81% reduction in surgeries for recurrent respir

PR NewswirePLYMOUTH MEETING, Pa., April 29, 2025 PLYMOUTH MEETING, Pa., April 29, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused

PR NewswirePLYMOUTH MEETING, Pa., April 9, 2025 PLYMOUTH MEETING, Pa., April 9, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused o

INOVIO (INO) will present key data on its lead candidate INO-3107 at several scientific conferences. INO-3107 shows a 72% overall response rate in Year

Release Date: March 18, 2025For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Inovio Pharmace

Refinitiv StreetEvents Event TranscriptE D I T E D V E R S I O NINO.OQ - Inovio Pharmaceuticals IncQ4 2024 Inovio Pharmaceuticals Inc Earnings CallMar 18, 202

The following slide deck was published by Inovio Pharmaceuticals, Inc.

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Q4 2024 Earnings Conference Call March 18, 2025 4:30 PM ETCompany ParticipantsJennie Willson - IRJacqui Shea -...

PR NewswirePLYMOUTH MEETING, Pa., March 18, 2025 Significant progress toward submitting a biologics license application (BLA) for INO-3107 as a potential t

Revenue: $0.117 million for Q4 2024, significantly above the estimated $0.03 million.Earnings Per Share (EPS): Reported EPS of -$0.65, outperforming the estima